Countrygirl
Senior Member
- Messages
- 5,638
- Location
- UK
About ten-per-cent of Corvid patients are developing an illness very similar or the same as those with ME, who also, in the main, became chronically ill after an acute viral infection such as Coxsackie B, Lyme, Q fever or exposure to toxic chemicals. Will their future be the same as that of the past of ME patients: will they also be ignored, even abused and abandoned by the medical profession or will medicine finally take this group of often bedbound/housebound patients seriously after 90 years of neglect and disbelief? What changes with the potential influx of new patients have on the continuing fate of this abandoned group of patients?
The post below is written by Dr David Tuller and Dr Mady Hornig
https://www.healthaffairs.org/do/10...E0fHa7KI-cLTiAd-LrGI36AkYQ4OvXvTDOik6Oped8ME&
HEALTH AFFAIRS BLOG
RELATED TOPICS:
Why Do Some Recover From COVID-19 Quickly, While Others Seem Likely To Face Long-Term Disability?
The post below is written by Dr David Tuller and Dr Mady Hornig
https://www.healthaffairs.org/do/10...E0fHa7KI-cLTiAd-LrGI36AkYQ4OvXvTDOik6Oped8ME&
HEALTH AFFAIRS BLOG
RELATED TOPICS:
Why Do Some Recover From COVID-19 Quickly, While Others Seem Likely To Face Long-Term Disability?
Never in the modern scientific era have so many people been infected with the same virus in such a short period of time. And if the history of medicine is a guide, a proportion of COVID-19 survivors will not fully recover and will develop disabling and chronic neurological dysfunctions and other disorders.
Benefits Beyond COVID-19
It is also important to recognize that such research has benefits that extend beyond just the population of individuals with COVID-19. For example, it could benefit up to 3.4 million Americans estimated to be suffering from myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS)—a disease or cluster of related diseases characterized by profound exhaustion after minimal exertion, sleep disorders, cognitive lapses, and other symptoms. Some get better, but few regain full function. A quarter of patients are largely home-bound or bed-bound. In the US, the annual costs of ME/CFS, including medical expenses and lost productivity, could be as much as $24 billion, according to the Centers for Disease Control and Prevention.
Many if not most ME/CFS patients date the start of their illness either to a case of mononucleosis, a cold, or some other acute infectious episode. Although efforts to link the condition to a specific pathogen have failed, viruses, bacteria, and parasites all appear capable of triggering these extended states of poor health.
Start The Research Now
Research on the long-term impacts of SARS and other epidemic diseases has often been retrospective—that is, it looks backward to determine why some patients continue to experience symptoms. Such investigations, while useful, provide much less authoritative and reliable information than prospective research that follows people from diagnosis and over an extended period of time. For example, biological samples acquired early on may reveal evidence of key aspects of the disease process. And patients might forget details that could be important clues to pathophysiologic changes if they are only asked about them after the fact.
With the coronavirus, now is the time to implement such prospective research and start documenting the biological pathways from initial illness to chronic neurological dysfunctions and other disorders. Some specialty medical associations and research groups have already initiated or announced valuable efforts to gather such data, yet post-COVID-19 monitoring and biobanking plans remain extremely limited and fragmented. Unless nationwide and global surveillance and registry mechanisms are established soon, our best opportunity to discover the factors that impede or hasten long-term recovery—and to translate these findings into effective interventions—will rapidly slip away.
Such an initiative would require bold leadership from the National Institutes of Health, to rally the cooperation of other key institutional governmental and non-governmental bodies, both domestic and international. And it would obviously require large funding commitments.But the unprecedented scale of events, and the potential economic, societal, and human toll of a secondary wave of post-COVID-19 disability, call for an unprecedented global research investment to meet this public health challenge head on.